Extension Study to Evaluate the Safety and Tolerability of NBI-921352 When Used With Anti-seizure Medications in Adults With Focal Onset Seizures

Focal Onset Seizure Clinical Trial

Official title: Prospective, Long-Term, Interventional, Active Extension Study to Evaluate the Safety and Tolerability of NBI-921352 as Adjunctive Therapy in Subjects With Focal Onset Seizures (FOS)

Status Terminated

Clinical Trial Summary

This Phase 2, prospective, interventional, active extension study was designed to evaluate the long-term safety and tolerability of NBI-921352 as adjunctive therapy in adult participants with focal onset seizures who completed 11 weeks of treatment in randomized, double-blind, placebo-controlled Study NBI-921352-FOS2021. Eligible participants may enroll directly following the completion of the Week 11 study visit of Study NBI-921352-FOS2021 or after a gap following completion of that study.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Epilepsy
• Focal Onset Epilepsy
• Seizures

• NCT number: NCT05493293
• Study type: Interventional
• Source: Neurocrine Biosciences
• Status: Terminated
• Phase: Phase 2
• Start date: November 9, 2022
• Completion date: March 11, 2024